Atossa Therapeutics declares stapled CVR dividend linked to potential priority review voucher proceeds

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced it has entered into a definitive Stapled Contingent Value Rights Agreement and declared a dividend of one stapled contingent value right (CVR) for each share of common stock outstanding as of October 19, 2026. The CVRs are linked to potential net proceeds from the first FDA priority review voucher that may be awarded to the company, with total payments capped at $50 million. The company issued a press release on October 9, 2026, announcing the execution of the CVR Agreement and declaration of the Record Date.